Selective BCL-X <sub>L</sub> Antagonists Eliminate Infected Cells from a Primary-Cell Model of HIV Latency but Not from <i>Ex Vivo</i> Reservoirs
Yanqin Ren, Szu-Han Huang, Amanda B. Macedo, Adam R. Ward, Winiffer D. Conce Alberto, Thaís Klevorn, Louise Leyre, Dennis C. Copertino, Talia M. Mota, Dora Chan, Ronald Truong, Thomas Rohwetter, Paul Zumbo, Friederike Dündar, Doron Betel, Colin Kovacs, Erika Benko, Alberto Bosque, R. Brad Jones
Abstract
Although antiretroviral therapy (ART) has transformed HIV infection into a manageable chronic condition, there is no safe or scalable cure. HIV persists in “reservoirs” of infected cells that reinitiate disease progression if ART is interrupted.
Topics & Concepts
BiologyEx vivoIonomycinViremiaImmunologyVirologyIn vivoIn vitroHuman immunodeficiency virus (HIV)GeneticsHIV Research and TreatmentImmune Cell Function and InteractionT-cell and B-cell Immunology